APLS vs. BPMC, BBIO, OGN, IONS, PRGO, NUVL, CYTK, ALPN, ELAN, and ALKS
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Nuvalent (NUVL), Cytokinetics (CYTK), Alpine Immune Sciences (ALPN), Elanco Animal Health (ELAN), and Alkermes (ALKS). These companies are all part of the "pharmaceutical preparations" industry.
Apellis Pharmaceuticals (NASDAQ:APLS) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends, media sentiment and community ranking.
Blueprint Medicines received 205 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. Likewise, 67.80% of users gave Blueprint Medicines an outperform vote while only 67.17% of users gave Apellis Pharmaceuticals an outperform vote.
Blueprint Medicines has a net margin of -102.15% compared to Apellis Pharmaceuticals' net margin of -133.34%. Apellis Pharmaceuticals' return on equity of -178.60% beat Blueprint Medicines' return on equity.
Apellis Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.
Apellis Pharmaceuticals currently has a consensus price target of $77.40, suggesting a potential upside of 76.31%. Blueprint Medicines has a consensus price target of $100.31, suggesting a potential downside of 7.59%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Apellis Pharmaceuticals is more favorable than Blueprint Medicines.
In the previous week, Blueprint Medicines had 39 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 51 mentions for Blueprint Medicines and 12 mentions for Apellis Pharmaceuticals. Blueprint Medicines' average media sentiment score of 0.47 beat Apellis Pharmaceuticals' score of 0.33 indicating that Blueprint Medicines is being referred to more favorably in the news media.
96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 7.5% of Apellis Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Blueprint Medicines has lower revenue, but higher earnings than Apellis Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Apellis Pharmaceuticals beats Blueprint Medicines on 10 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
